“点击蓝字 关注我们全球研发 | 复星医药子公司复宏汉霖下一代TCE四特异性抗体HLX3901获国家药监局IND许可PPS2026年3月9日，复星医药子公司复宏汉霖（2696.HK）宣布，基于自主研发的创新型T细胞衔接器（T-cell engager, TCE）平台开发的创新分子——HLX3901（DLL3 x DLL3 x CD3 x CD28 四特异性抗体）的新药临床试验（IND）申请已获得...
Source Link“点击蓝字 关注我们全球研发 | 复星医药子公司复宏汉霖下一代TCE四特异性抗体HLX3901获国家药监局IND许可PPS2026年3月9日，复星医药子公司复宏汉霖（2696.HK）宣布，基于自主研发的创新型T细胞衔接器（T-cell engager, TCE）平台开发的创新分子——HLX3901（DLL3 x DLL3 x CD3 x CD28 四特异性抗体）的新药临床试验（IND）申请已获得...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.